[go: up one dir, main page]

DK2032521T3 - Ny fremgangsmåde til saltfremstilling - Google Patents

Ny fremgangsmåde til saltfremstilling

Info

Publication number
DK2032521T3
DK2032521T3 DK07785845.4T DK07785845T DK2032521T3 DK 2032521 T3 DK2032521 T3 DK 2032521T3 DK 07785845 T DK07785845 T DK 07785845T DK 2032521 T3 DK2032521 T3 DK 2032521T3
Authority
DK
Denmark
Prior art keywords
new method
salt preparation
preparation
trialkylsilylhalogenide
hydroiodides
Prior art date
Application number
DK07785845.4T
Other languages
English (en)
Inventor
Josef Wieser
Hannes Lengauer
Hubert Sturm
Arthur Pichler
Elfriede Klingler
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37450796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2032521(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Application granted granted Critical
Publication of DK2032521T3 publication Critical patent/DK2032521T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Seasonings (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK07785845.4T 2006-06-27 2007-06-25 Ny fremgangsmåde til saltfremstilling DK2032521T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06116134 2006-06-27
PCT/EP2007/005596 WO2008000418A2 (en) 2006-06-27 2007-06-25 New method for salt preparation

Publications (1)

Publication Number Publication Date
DK2032521T3 true DK2032521T3 (da) 2010-01-25

Family

ID=37450796

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07785845.4T DK2032521T3 (da) 2006-06-27 2007-06-25 Ny fremgangsmåde til saltfremstilling

Country Status (14)

Country Link
US (1) US20100204470A1 (da)
EP (3) EP2145890B1 (da)
JP (1) JP2009541385A (da)
CN (1) CN101484411A (da)
AT (1) ATE446946T1 (da)
AU (1) AU2007264030B2 (da)
CA (1) CA2655061A1 (da)
DE (1) DE602007003024D1 (da)
DK (1) DK2032521T3 (da)
ES (1) ES2335369T3 (da)
PL (1) PL2032521T3 (da)
RU (1) RU2461542C2 (da)
SI (1) SI2032521T1 (da)
WO (1) WO2008000418A2 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
WO2007108011A2 (en) * 2006-03-20 2007-09-27 Ind-Swift Laboratories Limited Process for the preparation of highly pure donepezil
WO2008130630A2 (en) * 2007-04-16 2008-10-30 Teva Pharmaceutical Industries Ltd. Polymorphic form of rimonabant hydrochloride and processes for preparation thereof
EP2213665A1 (en) 2007-08-17 2010-08-04 Hetero Drugs Limited Erlotinib hydrochloride
DE112009000268T5 (de) 2008-02-06 2011-06-01 Helm Ag Prasugrel-Salze mit verbesserten Eigenschaften
WO2009125426A2 (en) * 2008-02-08 2009-10-15 Neuland Laboratories Ltd NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE
CA2739897C (en) 2008-10-07 2017-10-03 Mpex Pharmaceuticals, Inc. Aerosol fluoroquinolone formulations for improved pharmacokinetics
EP2346509B1 (en) 2008-10-07 2020-05-13 Horizon Orphan LLC Inhalation of levofloxacin for reducing lung inflammation
EP2411373B1 (en) 2009-03-26 2015-10-21 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
WO2010111951A1 (zh) * 2009-03-31 2010-10-07 上海医药工业研究院 普拉格雷氢溴酸盐的晶体
EP2236509A1 (en) 2009-04-01 2010-10-06 Ragactives, S.L. Method for obtaining 1,3-difunctionalized pyrrolidine derivatives
RU2015130524A (ru) 2009-09-04 2018-12-21 Раптор Фармасьютикалз Инк. Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза
US20120302749A1 (en) 2009-11-12 2012-11-29 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
CZ2009828A3 (cs) 2009-12-09 2011-06-22 Zentiva, K.S. Zpusob prípravy hydrochloridu 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu (prasugrelu hydrochloridu) v polymorfní forme B
CN102212071B (zh) * 2010-04-08 2014-03-26 上海医药工业研究院 普拉格雷盐酸盐乙酸溶剂合物及其结晶和制备方法
PL2448945T3 (pl) * 2010-04-08 2015-06-30 Teva Pharma Krystaliczne postacie soli prasugrelu
CN102342921B (zh) * 2010-08-01 2013-09-11 江苏正大天晴药业股份有限公司 普拉格雷氢溴酸盐醋酸合物的药物组合物
EP2447256A1 (en) 2010-10-21 2012-05-02 Laboratorios Lesvi, S.L. Process for obtaining dronedarone
IT1403083B1 (it) * 2010-10-25 2013-10-04 Fidia Farmaceutici Nuova forma polimorfa di raloxifene cloridrato
EP2681220B1 (en) 2011-03-03 2015-08-19 Cadila Healthcare Limited Novel crystalline form of a dpp-iv inhibitor
SI2691083T1 (sl) * 2011-03-29 2017-12-29 Krka, D.D., Novo Mesto Farmacevtski sestavek sitagliptina
KR101766835B1 (ko) 2011-05-04 2017-08-09 에스프린팅솔루션 주식회사 화상형성장치 및 그 제어 방법
US20150025080A1 (en) 2011-06-29 2015-01-22 Ranbaxy Laboratories Limited Solid dispersions of sitagliptin and processes for their preparation
AU2012277403A1 (en) 2011-06-30 2014-01-30 Ranbaxy Laboratories Limited Novel salts of sitagliptin
EP2788352A1 (en) 2011-12-08 2014-10-15 Ranbaxy Laboratories Limited Amorphous form of sitagliptin salts
EP2882291B1 (en) * 2012-08-07 2017-09-27 ZCL Chemicals Ltd. An improved process for the preparation of memantine hydrochloride
WO2014037961A1 (en) 2012-09-04 2014-03-13 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
CN103012427B (zh) * 2012-11-26 2015-07-08 天津大学 一种普拉格雷盐酸盐乙醇溶剂化物及其制备方法
PL402028A1 (pl) 2012-12-12 2014-06-23 Instytut Farmaceutyczny Sposób wytwarzania postaci polimorficznej B chlorowodorku prasugrelu o czystości farmaceutycznej
CN103739500B (zh) * 2012-12-27 2016-03-23 国药一心制药有限公司 一种盐酸西那卡塞的合成与精制方法
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
WO2014135834A1 (en) * 2013-03-05 2014-09-12 Cipla House Oxalic acid addition salts and/or solvates of a selective estrogen receptor modulator
CN103145628B (zh) * 2013-03-18 2015-04-22 齐鲁制药有限公司 一种厄洛替尼一水合物晶型i的制备方法
CN104072442B (zh) * 2013-03-28 2016-09-28 成都弘达药业有限公司 一种化合物及其制备方法
CN103396371B (zh) * 2013-08-26 2015-12-02 南京优科生物医药研究有限公司 一种盐酸埃罗替尼晶型a的制备方法
IN2014MU00651A (da) 2014-02-25 2015-10-23 Cadila Healthcare Ltd
WO2015170340A2 (en) * 2014-05-06 2015-11-12 Laurus Labs Private Limited Novel polymorphs of sitagliptin hydrochloride, processes for its preparation and pharmaceutical composition thereof
CN107540634A (zh) * 2016-06-27 2018-01-05 江苏神龙药业股份有限公司 一种普拉克索单盐酸盐的新晶型及其制备方法
CN107540632A (zh) * 2016-06-27 2018-01-05 江苏神龙药业股份有限公司 一种普拉克索单盐酸盐的新晶型及其制备方法
CN111107847A (zh) 2017-09-26 2020-05-05 细胞内治疗公司 新的盐和晶体
MX2020013116A (es) 2018-06-06 2021-05-12 Intra Cellular Therapies Inc Sales y cristales novedosos.
SG11202012095XA (en) * 2018-06-06 2021-01-28 Minoryx Therapeutics S L Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
KR102874906B1 (ko) * 2018-12-14 2025-10-21 치아타이 티안큉 파마수티컬 그룹 주식회사 Syk 억제제의 염 및 이의 결정형
CN116367833B (zh) * 2020-11-19 2025-02-25 四川科伦药物研究院有限公司 苯并噻唑类化合物的盐及其晶体形式和用途
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU46919B (sh) * 1988-07-13 1994-06-24 Krka Tovarna Zdravil N.Sol.O. Postupak za dobijanje derivata l-alanil-l-prolina
TW209865B (da) 1992-01-10 1993-07-21 Bayer Ag
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
RU2132849C1 (ru) 1993-09-15 1999-07-10 Синтекс (Ю.ЭС.ЭЙ.) Инк. Кристаллический безводный микофенолят мофетила, внутривенная композиция на его основе, состав, пригодный для получения водной внутривенной композиции
DE19546249A1 (de) 1995-12-12 1997-06-19 Bayer Ag Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
WO1997046527A1 (en) 1996-06-07 1997-12-11 Eisai Co., Ltd. Polymorphs of donepezil hydrochloride and process for production
CA2309332C (en) 1997-11-12 2002-12-03 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
EP1728794B1 (en) 2000-07-06 2008-06-18 Daiichi Sankyo Company, Limited Maleate addition salt of hydropyridine derivatives
HUP0303496A3 (en) 2000-10-19 2005-08-29 Teva Pharma Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
AU2002212340B2 (en) 2000-10-31 2006-12-14 Sandoz Ag Crystalline forms of venlafaxine hydrochloride
MXPA03005770A (es) * 2000-12-25 2003-09-10 Sankyo Co Composiciones medicinales que contienen aspirina.
DE10153345A1 (de) * 2001-10-29 2003-05-08 Gruenenthal Gmbh Substituierte 1H-Chinoxalin-2-on-Verbindungen und substituierte 4-Aryl- und 4-Heteroarylcyclohexan-Verbindungen
UA77234C2 (en) 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
DE10161818A1 (de) * 2001-12-14 2003-06-26 Gruenenthal Gmbh Substituierte 1,5-Diaminopentan-3-ol-Verbindungen
DE10261091A1 (de) * 2002-12-20 2004-07-01 Grünenthal GmbH Gesättigte und ungesättigte Heteroarylcycloalkylmethyl-Amine
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
AU2003230192A1 (en) 2003-03-21 2004-10-11 Hetero Drugs Limited Novel crystalline forms of aripiprazole
US20060217351A1 (en) * 2003-05-05 2006-09-28 Brandt John T Method for treating cardiovascular diseases
EP1651630A1 (en) * 2003-08-05 2006-05-03 Matrix Laboratories Ltd An improved process for the preparation of moxifloxacin hydrochloride
EP1685130B1 (en) 2003-11-20 2008-12-10 CHEMI S.p.A. Polymorphs of 1-cyclopropyl-7-([s,s] - 2,8-diazadicyclo [4.3.0] non-8-yl) -6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride and methods for the preparation thereof
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
JP2008512417A (ja) * 2004-09-10 2008-04-24 ユセベ ファルマ ソシエテ アノニム シグマ受容体リガンド

Also Published As

Publication number Publication date
JP2009541385A (ja) 2009-11-26
PL2032521T3 (pl) 2010-05-31
WO2008000418A3 (en) 2008-02-28
EP2032521B1 (en) 2009-10-28
EP2032521A2 (en) 2009-03-11
EP2436381A1 (en) 2012-04-04
WO2008000418A2 (en) 2008-01-03
CN101484411A (zh) 2009-07-15
ES2335369T3 (es) 2010-03-25
RU2009102279A (ru) 2010-08-10
EP2145890B1 (en) 2012-08-01
US20100204470A1 (en) 2010-08-12
EP2145890A3 (en) 2010-03-31
CA2655061A1 (en) 2008-01-03
DE602007003024D1 (de) 2009-12-10
EP2145890A2 (en) 2010-01-20
AU2007264030A1 (en) 2008-01-03
ATE446946T1 (de) 2009-11-15
SI2032521T1 (sl) 2010-02-26
AU2007264030B2 (en) 2012-04-05
RU2461542C2 (ru) 2012-09-20

Similar Documents

Publication Publication Date Title
DK2032521T3 (da) Ny fremgangsmåde til saltfremstilling
MA29135B1 (fr) Potentialisateurs de recepteurs du glutamate
SMT201400142B (it) Composti di N-(1H-indazol-4-il) immidazo[1,2-A]piridin-3-carbossammide sostituita come inibitori di cfms
ATE538115T1 (de) Kondensierte anthranilsäureamidderivate als insektizide
ATE405570T1 (de) Hiv-integrase-inhibitoren: cyclische pyrimidinonverbindung
TNSN07277A1 (en) Pharmaceutical compounds
DK2019090T3 (da) Substitueret beta-phenyl-alfa-hydroxypropansyre, fremgangsmåde til syntese og anvendelse deraf
DOP2007000107A (es) Nitrilos espirocíclicos como inhibidores de proteasa
DK1937633T3 (da) Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme
CR11824A (es) Derivados heterocíclicos de la urea y sus métodos de empleo
MX2009004290A (es) Inhibidores de proteasas de catepsina.
DE60216641D1 (de) Polymorph von 4-ä2-ä4-ä1-(2-ethoxyethyl)-1h-benzimidazol-2-ylü-1-piperidinylüethylü-alpha, alpha-dimethylbenzolessigsäure
NO20081617L (no) Metoder for fremstilling av Glutaminsyrederivater
EA200700766A1 (ru) Способ получения производных [1,4,5]-оксадиазепина
DK1723140T3 (da) Fremgangsmåde til fremstilling af tryptase-inhibitorer
DK2402306T3 (da) Fremgangsmåde til fremstilling af 5-aminolaevulinsyrehydrochlorid
DK2265580T3 (da) Hidtil ukendt fremgangsmåde til fremstillingen af sulfonylpyrroler som HDAC-inhibitorer
ITMI20060764A1 (it) Rettificatirce di provini cilindrici,particolarmente di calcestruzzo
EA200901229A1 (ru) Новый способ получения левоцетиризина и его промежуточных соединений
ATE546451T1 (de) Cyclopropancarbonsäureester von acyclovir
TW200639167A (en) Pharmaceutical compounds
NO20064410L (no) Fremgangsmate for fremstilling av tryptaseinhibitorer
TH148538B (th) อนุพันธ์ของ n-(แอริลอะมิโน) ซัลโฟนาไมด์ ที่รวมถึงพหุสัณฐานในฐานะตัวยับยั้งของ mek และสารองค์ประกอบ,วิธีการของการใช้ และวิธีการสำหรับการเตรียมสารชนิดเดียวกันนั้น
TW200740756A (en) Potentiator of glutamate receptors
TH132950A (th) สารประกอบ, องค์ประกอบ และ วิธีการบางอย่าง